SAB Biotherapeutics (SABS) Revenue (2021 - 2024)
SAB Biotherapeutics' (SABS) quarterly Revenue came in at $114698.0 in Q4 2024, down 62.4% YoY from $305011.0 in Q1 2024, and down 56.41% on a QoQ basis from $263137.0 in Q2 2024.
SAB Biotherapeutics (SABS) Revenue (2021 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of Revenue data on file, last reported at $114698.0 in Q4 2024.
- Quarterly Revenue fell 62.4% year-over-year to $114698.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.3 million (down 40.94% YoY) and the FY2024 annual result came in at $1.3 million, down 40.94% from the prior year.
- Revenue slipped to $114698.0 in Q4 2024, from $263137.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $18.2 million in Q2 2021 to a low of $85518.0 in Q2 2023.
- A 4-year average of $5.9 million and a median of $2.2 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue sank 98.65% — and 2024, when it surged 207.7%.
- Tracing SABS's Revenue over 4 years: stood at $11.1 million in 2021, then slumped by 80.46% to $2.2 million in 2022, then tumbled by 85.88% to $305011.0 in 2023, then tumbled by 62.4% to $114698.0 in 2024.
- The last three Revenue figures came in at $114698.0 (Q4 2024), $263137.0 (Q2 2024), and $944575.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 114,698.00 |
| Jun 30, 2024 | 263,137.00 |
| Mar 31, 2024 | 944,575.00 |
| Dec 31, 2023 | 305,011.00 |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 85,518.00 |
| Mar 31, 2023 | 581,101.00 |
| Dec 31, 2022 | 2.16 Mn |
| Sep 30, 2022 | 3.59 Mn |
| Jun 30, 2022 | 6.35 Mn |
| Mar 31, 2022 | 11.80 Mn |
| Dec 31, 2021 | 11.06 Mn |
| Sep 30, 2021 | 14.68 Mn |
| Jun 30, 2021 | 18.21 Mn |
| Mar 31, 2021 | 16.93 Mn |